Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology

Impact · against what's priced in

Astellas gains a potential best-in-class immuno-oncology asset through a structured option agreement with Audax Biosciences. While the total deal value is significant, the majority of costs are deferred milestones and clinical data is not expected until late 2027 or 2028, limiting the immediate impact on valuation.

4503+0.40

No priced-in read yet